Stay updated on SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial
Sign up to get notified when there's something new on the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page.

Latest updates to the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing v3.5.3, representing a minor version update.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedClinicalTrials.gov updated the study record revision/date and refined the treatment regimen details (e.g., calaspargase pegol administration description) and monitoring language for trial procedures. It also updated key eligibility/evaluability and primary/expansion outcome descriptions, including the DLT evaluability thresholds for dose-finding and how MRD-negative remission is described for patients under 6 months.SummaryDifference0.9%

- Check41 days agoChange Detected- Page revision updated to v3.5.2.SummaryDifference0.0%

- Check56 days agoChange DetectedAdded MRD-negative remission rate endpoints for infants and older infants, and expanded exploratory objectives to include PK analyses of calaspargase pegol within the revumenib-plus-chemotherapy regimen. Updated regimen descriptions and cycle structure, and removed certain MRD and PK items from the previous version.SummaryDifference0.8%

- Check70 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page. The change appears to be a global versioning update with no visible edits to study details or user-facing content.SummaryDifference0.0%

- Check85 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page.